{"id":20675,"date":"2023-01-09T17:37:53","date_gmt":"2023-01-09T12:07:53","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=20675"},"modified":"2023-09-05T17:18:12","modified_gmt":"2023-09-05T11:48:12","slug":"eosinophilic-esophagitis-treatment-outlook","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/eosinophilic-esophagitis-treatment-outlook","title":{"rendered":"Is it the Dawn of Biologics in the Eosinophilic Esophagitis Treatment Landscape?"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69d1543d1d483\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69d1543d1d483\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/eosinophilic-esophagitis-treatment-outlook\/#Rising_Prevalence_and_Promising_Eosinophilic_Esophagitis_Pipeline_%E2%80%93_the_Perfect_Catalyst_for_a_Market_With_High_Growth_Potential\" >Rising Prevalence and Promising Eosinophilic Esophagitis Pipeline \u2013 the Perfect Catalyst for a Market With High Growth Potential<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/eosinophilic-esophagitis-treatment-outlook\/#Whats_Cooking_in_the_Eosinophilic_Esophagitis_Treatment_Space\" >What\u2019s Cooking in the Eosinophilic Esophagitis Treatment Space?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/eosinophilic-esophagitis-treatment-outlook\/#Whats_Ahead_in_the_Eosinophilic_Esophagitis_Treatment_Market\" >What\u2019s Ahead in the Eosinophilic Esophagitis Treatment Market?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/eosinophilic-esophagitis-treatment-outlook\/#FAQs\" >FAQs<\/a><\/li><\/ul><\/nav><\/div>\n\n<p>Eosinophilic Esophagitis (EoE) is a chronic inflammatory ailment that is immune-mediated. It is characterized by an increased number of eosinophils infiltrating the esophagus, thus, impacting one\u2019s fundamental eating ability. It affects both adults and children and is caused by allergens; food antigens are considered the main precursors of EoE, although other genetic and environmental factors are also known. The incident and prevalent cases of EoE have been on an upsurge at an outpaced rate<strong> <\/strong>not just because of increased awareness or better diagnosis but also due to the understanding of the pathophysiology along with an increase in the number of other potential risk factors like food and air allergens, early-life exposures to proton pumps or antibiotics, acid suppressants, and preterm birth, etc.&nbsp;<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><strong>As per Delveinsight analysis, this increase in <a href=\"https:\/\/www.delveinsight.com\/report-store\/eosinophilic-esophagitis-epidemiology-forecast\">eosinophilic esophagitis prevalence<\/a> is expected to reach 1 billion by 2032 among the seven major markets.<\/strong><\/p>\n<\/blockquote>\n\n\n\n<p>Until 2022, the eosinophilic esophagitis treatment was managed by <strong>dietary eliminations and medical treatments<\/strong> like proton pump inhibitors and swallowed topical steroids (budesonide and fluticasone), which helped relieve symptoms and inflammation. However, in the first half of 2022, the US FDA approved the usage o<strong>f <\/strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/dupixent-drug-insight-and-market-forecast\"><strong>DUPIXENT (dupilumab)<\/strong><\/a> \u2014 the first and the only biologic to show meaningful clinical data for eosinophilic esophagitis treatment in adults and pediatric patients 12 years and older. Further, by investigating the potential use of DUPIXENT in children with EoE aged 1\u201311, <strong>Sanofi\/Regeneron<\/strong> could be the first pharma giant to mark its presence with a therapeutic asset catering to this age group.<\/p>\n\n\n\n<h2 class=\"wp-block-heading advgb-dyn-f5c2cd66\" id=\"h-rising-prevalence-and-promising-eosinophilic-esophagitis-pipeline-the-perfect-catalyst-for-a-market-with-high-growth-potential\"><span class=\"ez-toc-section\" id=\"Rising_Prevalence_and_Promising_Eosinophilic_Esophagitis_Pipeline_%E2%80%93_the_Perfect_Catalyst_for_a_Market_With_High_Growth_Potential\"><\/span><strong>Rising Prevalence and Promising Eosinophilic Esophagitis Pipeline \u2013 the Perfect Catalyst for a Market With High Growth Potential<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>As per Delveinsight\u2019s analysis, the <a href=\"https:\/\/www.delveinsight.com\/report-store\/eosinophilic-esophagitis-market\">eosinophilic esophagitis treatment market<\/a> is estimated to increase at a <strong>CAGR of 26%<\/strong> during the study period 2019\u20132032.&nbsp;<\/p>\n\n\n\n<p>Besides a significant expected rise in prevalence, the emerging eosinophilic esophagitis treatment space shows potential with a couple of mAbs, apart from dupilumab, waiting in line for their approval in EoE. <strong>FASENRA (benralizumab; AstraZeneca\/Kyowa Hakko Kirin) <\/strong>and<strong> cendakimab (Bristol Myers Squibb)<\/strong> are the two mAbs in late-stage clinical development. Further, a reformulation of fluticasone propionate\u2014<strong>APT-1011 (Ellodi Pharmaceuticals)<\/strong> is also being investigated in Phase III eosinophilic esophagitis clinical trials. It has also received <strong>Fast Track Designation<\/strong> from the US FDA.&nbsp;<\/p>\n\n\n\n<p>However,<strong> Takeda\u2019s <\/strong>decision to discontinue launching Eohilia for EoE has been a game-changer for other <a href=\"https:\/\/www.delveinsight.com\/report-store\/eosinophilic-esophagitis-pipeline-insight\">eosinophilic esophagitis therapies<\/a>. Takeda was the first to file for FDA approval, but the regulatory body issued a complete response letter mentioning that the drug could not be approved and recommended additional studies. This led to Takeda ceasing launch-related activities for Eoholia.&nbsp;<\/p>\n\n\n\n<figure class=\"wp-block-image size-full is-resized\"><img decoding=\"async\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/01\/09112507\/Eosinophilic-Esophagitis-Pipeline-Assessment.png\" alt=\"eosinophilic esophagitis pipeline\" class=\"wp-image-20680\" width=\"973\" height=\"300\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/01\/09112507\/Eosinophilic-Esophagitis-Pipeline-Assessment.png 973w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/01\/09112507\/Eosinophilic-Esophagitis-Pipeline-Assessment-300x92.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/01\/09112507\/Eosinophilic-Esophagitis-Pipeline-Assessment-150x46.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/01\/09112507\/Eosinophilic-Esophagitis-Pipeline-Assessment-768x237.png 768w\" sizes=\"(max-width: 973px) 100vw, 973px\" \/><figcaption class=\"wp-element-caption\"><strong>Promising Therapies in the Eosinophilic Esophagitis Pipeline<\/strong><\/figcaption><\/figure>\n\n\n\n<p>While Eohilia\u2019s exit shifts the focus on other potential assets, APT-1011, being a similar asset (i.e., reformulation of fluticasone), is under the spotlight. Whether <strong>Ellodi\u2019s APT-1011<\/strong> will face a similar consequence or prove its safety and efficacy remains doubtful. If approved, APT-1011 will generate approximately <strong>USD 220 million<\/strong> by 2032, as per DelveInsight\u2019s estimates.&nbsp;<\/p>\n\n\n\n<h2 class=\"wp-block-heading advgb-dyn-16e985dd\"><span class=\"ez-toc-section\" id=\"Whats_Cooking_in_the_Eosinophilic_Esophagitis_Treatment_Space\"><\/span><strong>What\u2019s Cooking in the Eosinophilic Esophagitis Treatment Space?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li>In <strong>December 2022, Regeneron Pharmaceuticals, Inc. and Sanofi<\/strong> announced that the New England Journal of Medicine published results from a positive Phase III trial in which adults and adolescents treated with Dupixent\u00ae (dupilumab) 300 mg weekly experienced significant improvements in signs and symptoms of eosinophilic esophagitis (EoE) that lasted up to a year.<\/li>\n\n\n\n<li>In <strong>December 2022, Sanofi and partner Regeneron<\/strong> announced that the European Medicines Agency\u2019s Committee for Medicinal Products for Human Use (CHMP) had recommended approval of Dupixent (dupilumab) for the treatment of adults and adolescents with eosinophilic esophagitis, a chronic inflammatory disease.<\/li>\n\n\n\n<li>In <strong>November 2022, Revolo Biotherapeutics<\/strong>, a company developing therapies that reset the immune system to achieve superior long-term remission for patients with autoimmune and allergic diseases, announced that the last patient had completed a Phase IIa proof of concept clinical study investigating its immune-resetting molecule, \u20181104, for the treatment of eosinophilic esophagitis (EoE).<\/li>\n\n\n\n<li>In <strong>October 2022, Eupraxia Pharmaceuticals Inc.<\/strong>, a Phase II clinical-stage biotechnology company with an innovative drug delivery technology platform, announced the start of a Phase II trial of EP-104IAR in adult <a href=\"https:\/\/www.delveinsight.com\/report-store\/eosinophilic-esophagitis-epidemiology-forecast\">patients with eosinophilic esophagitis (EoE)<\/a>, a rare disease that impairs swallowing and has a significant impact on quality of life.<\/li>\n\n\n\n<li>In <strong>October 2022, Regeneron Pharmaceuticals, Inc.<\/strong> and <strong>Sanofi <\/strong>announced late-breaking positive results from a Phase III trial of Dupixent\u00ae (dupilumab) in children aged 1 to 11 years with active eosinophilic esophagitis (EoE).<\/li>\n\n\n\n<li>In <strong>May 2022, Sanofi and its partner Regeneron<\/strong> announced that the FDA had approved Dupixent (dupilumab) for a new indication, eosinophilic esophagitis (EoE).<\/li>\n\n\n\n<li>In <strong>March 2022<\/strong>, <strong>Pfizer Inc<\/strong>. announced the completion of its <strong>acquisition<\/strong> of <strong>Arena Pharmaceuticals<\/strong>, a clinical stage company developing innovative potential therapies for the treatment of several immuno-inflammatory diseases.\u00a0 Arena Pharmaceuticals brings to Pfizer a portfolio of diverse and promising development-stage therapeutic candidates in gastroenterology, dermatology, and cardiology, including etrasimod, an oral, selective <strong>sphingosine 1-phosphate (S1P) receptor modulator<\/strong> currently in development for a range of immuno-inflammatory diseases including ulcerative colitis, Crohn\u2019s Disease, atopic dermatitis, <strong>eosinophilic esophagitis,<\/strong> and alopecia areata.<\/li>\n<\/ul>\n\n\n\n<figure class=\"wp-block-image size-large is-resized\"><a href=\"https:\/\/www.delveinsight.com\/infographics\/eosinophilic-esophagitis-market\"><img decoding=\"async\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/09\/05171740\/Eosinophilic-Esophagitis-Market-Outlook-1024x194.webp\" alt=\"Eosinophilic Esophagitis Market Outlook\" class=\"wp-image-24813\" width=\"1024\" height=\"194\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/09\/05171740\/Eosinophilic-Esophagitis-Market-Outlook-1024x194.webp 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/09\/05171740\/Eosinophilic-Esophagitis-Market-Outlook-300x57.webp 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/09\/05171740\/Eosinophilic-Esophagitis-Market-Outlook-150x28.webp 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/09\/05171740\/Eosinophilic-Esophagitis-Market-Outlook-768x145.webp 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/09\/05171740\/Eosinophilic-Esophagitis-Market-Outlook-1536x291.webp 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/09\/05171740\/Eosinophilic-Esophagitis-Market-Outlook-1568x297.webp 1568w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/09\/05171740\/Eosinophilic-Esophagitis-Market-Outlook.webp 1584w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n\n\n\n<h2 class=\"wp-block-heading advgb-dyn-5b7e6908\"><span class=\"ez-toc-section\" id=\"Whats_Ahead_in_the_Eosinophilic_Esophagitis_Treatment_Market\"><\/span><strong>What\u2019s Ahead in the Eosinophilic Esophagitis Treatment Market?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>While there is no approved <a href=\"https:\/\/www.delveinsight.com\/report-store\/eosinophilic-esophagitis-market\">eosinophilic esophagitis treatment<\/a> in the US, Europe had JORVEZA by Dr. Falk Pharma, which was approved in 2018. JORVEZA is indicated for eosinophilic esophagitis treatment in adults aged 18 and above, and it is an orodispersible tablet \u2014 a more convenient and reliable way of delivering budesonide.<\/p>\n\n\n\n<p>Despite the favorable therapeutic effects of biologics, the approval of DUPIXENT, coupled with the promising biologics in the <a href=\"https:\/\/www.delveinsight.com\/report-store\/eosinophilic-esophagitis-pipeline-insight\">eosinophilic esophagitis pipeline<\/a>, invites questions about their high costs. Understanding cost-effectiveness becomes paramount, along with providing proper patient access. Cost-effectiveness evaluations will help payers, providers, and policymakers in decision-making. Although biologics are expensive eosinophilic esophagitis treatments, they are likely to be more cost-effective when used as a part of precision medicine.&nbsp; Moreover, a better understanding of the pathophysiology and mechanism of DNA instability and the impact of current eosinophilic esophagitis treatments on disease progression will help shape future clinical practice.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large is-resized\"><a href=\"https:\/\/www.delveinsight.com\/report-store\/eosinophilic-esophagitis-market\"><img decoding=\"async\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/01\/09112429\/Eosinophilic-Esophagitis-Market-Outlook-1024x256.png\" alt=\"Eosinophilic Esophagitis Market Outlook\" class=\"wp-image-20679\" width=\"1024\" height=\"256\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/01\/09112429\/Eosinophilic-Esophagitis-Market-Outlook-1024x256.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/01\/09112429\/Eosinophilic-Esophagitis-Market-Outlook-300x75.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/01\/09112429\/Eosinophilic-Esophagitis-Market-Outlook-150x38.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/01\/09112429\/Eosinophilic-Esophagitis-Market-Outlook-768x192.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/01\/09112429\/Eosinophilic-Esophagitis-Market-Outlook-1536x384.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/01\/09112429\/Eosinophilic-Esophagitis-Market-Outlook-1568x392.png 1568w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/01\/09112429\/Eosinophilic-Esophagitis-Market-Outlook.png 1584w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n\n\n\n<h2 class=\"wp-block-heading advgb-dyn-704ba596\"><span class=\"ez-toc-section\" id=\"FAQs\"><\/span><strong>FAQs<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<div class=\"schema-faq wp-block-yoast-faq-block\"><div class=\"schema-faq-section\" id=\"faq-question-1673242859637\"><strong class=\"schema-faq-question\"><strong>1. What is eosinophilic esophagitis?<\/strong><\/strong> <p class=\"schema-faq-answer\">Eosinophilic Esophagitis (EoE) is a chronic inflammatory ailment that is immune-mediated. It is characterized by an increased number of eosinophils infiltrating the esophagus, thus, impacting one\u2019s fundamental eating ability.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1673242872902\"><strong class=\"schema-faq-question\"><strong>2. What are the eosinophilic esophagitis symptoms?<\/strong><\/strong> <p class=\"schema-faq-answer\">Dysphagia, food impaction, and choking\/gagging with meals, particularly when eating coarse textures, are the most common eosinophilic esophagitis symptoms in school-aged children and adolescents, whereas dysphagia is more common in adults. Other eosinophilic esophagitis symptoms include abdominal\/chest pain, vomiting, and regurgitation.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1673242886155\"><strong class=\"schema-faq-question\"><strong>3. How is eosinophilic esophagitis diagnosed?<\/strong><\/strong> <p class=\"schema-faq-answer\">The clinical manifestations of EoE, as well as endoscopic and histological findings in esophageal mucosa biopsies, are used to make the eosinophilic esophagitis diagnosis. Biopsy findings demonstrating increased intra-epithelial esophageal eosinophil counts without concomitant eosinophilic infiltration in the stomach or duodenum remain the gold standard for eosinophilic esophagitis diagnosis.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1673242904796\"><strong class=\"schema-faq-question\"><strong>4. What are the current eosinophilic esophagitis treatment options?<\/strong><\/strong> <p class=\"schema-faq-answer\">Eosinophilic esophagitis treatment currently consists of dietary, pharmacological, and endoscopic interventions. PPIs and corticosteroids are the mainstays of treatment in pharmacologic therapy. PPIs and corticosteroids, unfortunately, are associated with a high rate of remission.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1673242929632\"><strong class=\"schema-faq-question\"><strong>5. Which pharma companies are currently working in the eosinophilic esophagitis treatment domain?<\/strong><\/strong> <p class=\"schema-faq-answer\">Leading companies, including Bristol Myers Squibb (BMS), Ellodi Pharmaceuticals, AstraZeneca, Kyowa Hakko Kirin, Dr. Falk Pharma GmbH, Regeneron Pharmaceuticals, Sanofi, Allakos, Pfizer, Revolo Biotherapeutics, EsoCap AG, and others are currently evaluating their lead assets in various clinical stages.<\/p> <\/div> <\/div>\n","protected":false},"excerpt":{"rendered":"<p>Eosinophilic Esophagitis (EoE) is a chronic inflammatory ailment that is immune-mediated. It is characterized by an increased number of eosinophils infiltrating the esophagus, thus, impacting one\u2019s fundamental eating ability. It affects both adults and children and is caused by allergens; food antigens are considered the main precursors of EoE, although other genetic and environmental factors [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":20676,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":5,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[20134,17001,20131,20133,20130,20132],"industry":[17225],"therapeutic_areas":[17239],"class_list":["post-20675","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-eoe","tag-eosinophilic-esophagitis","tag-eosinophilic-esophagitis-market","tag-eosinophilic-esophagitis-pipeline","tag-eosinophilic-esophagitis-treatment","tag-eosinophilic-esophagitis-treatment-market","industry-pharmaceutical","therapeutic_areas-gastroenterology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Promising Drugs for Eosinophilic Esophagitis Treatment in Pipeline<\/title>\n<meta name=\"description\" content=\"The emerging eosinophilic esophagitis treatment market shows potential with a couple of mAbs waiting in line for their approval in EoE space.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/eosinophilic-esophagitis-treatment-outlook\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Promising Drugs for Eosinophilic Esophagitis Treatment in Pipeline\" \/>\n<meta property=\"og:description\" content=\"The emerging eosinophilic esophagitis treatment market shows potential with a couple of mAbs waiting in line for their approval in EoE space.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/eosinophilic-esophagitis-treatment-outlook\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2023-01-09T12:07:53+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-09-05T11:48:12+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/01\/09111958\/eosinophilic-esophagitis-treatment-outlook.png\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Sandeep Joshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandeep Joshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Promising Drugs for Eosinophilic Esophagitis Treatment in Pipeline","description":"The emerging eosinophilic esophagitis treatment market shows potential with a couple of mAbs waiting in line for their approval in EoE space.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/eosinophilic-esophagitis-treatment-outlook","og_locale":"en_US","og_type":"article","og_title":"Promising Drugs for Eosinophilic Esophagitis Treatment in Pipeline","og_description":"The emerging eosinophilic esophagitis treatment market shows potential with a couple of mAbs waiting in line for their approval in EoE space.","og_url":"https:\/\/www.delveinsight.com\/blog\/eosinophilic-esophagitis-treatment-outlook","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2023-01-09T12:07:53+00:00","article_modified_time":"2023-09-05T11:48:12+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/01\/09111958\/eosinophilic-esophagitis-treatment-outlook.png","type":"image\/png"}],"author":"Sandeep Joshi","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Sandeep Joshi","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":["WebPage","FAQPage"],"@id":"https:\/\/www.delveinsight.com\/blog\/eosinophilic-esophagitis-treatment-outlook","url":"https:\/\/www.delveinsight.com\/blog\/eosinophilic-esophagitis-treatment-outlook","name":"Promising Drugs for Eosinophilic Esophagitis Treatment in Pipeline","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/eosinophilic-esophagitis-treatment-outlook#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/eosinophilic-esophagitis-treatment-outlook#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/01\/09111958\/eosinophilic-esophagitis-treatment-outlook.png","datePublished":"2023-01-09T12:07:53+00:00","dateModified":"2023-09-05T11:48:12+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"description":"The emerging eosinophilic esophagitis treatment market shows potential with a couple of mAbs waiting in line for their approval in EoE space.","mainEntity":[{"@id":"https:\/\/www.delveinsight.com\/blog\/eosinophilic-esophagitis-treatment-outlook#faq-question-1673242859637"},{"@id":"https:\/\/www.delveinsight.com\/blog\/eosinophilic-esophagitis-treatment-outlook#faq-question-1673242872902"},{"@id":"https:\/\/www.delveinsight.com\/blog\/eosinophilic-esophagitis-treatment-outlook#faq-question-1673242886155"},{"@id":"https:\/\/www.delveinsight.com\/blog\/eosinophilic-esophagitis-treatment-outlook#faq-question-1673242904796"},{"@id":"https:\/\/www.delveinsight.com\/blog\/eosinophilic-esophagitis-treatment-outlook#faq-question-1673242929632"}],"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/eosinophilic-esophagitis-treatment-outlook"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/eosinophilic-esophagitis-treatment-outlook#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/01\/09111958\/eosinophilic-esophagitis-treatment-outlook.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/01\/09111958\/eosinophilic-esophagitis-treatment-outlook.png","width":772,"height":482,"caption":"eosinophilic-esophagitis-treatment-outlook"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a","name":"Sandeep Joshi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","caption":"Sandeep Joshi"},"sameAs":["http:\/\/Delveinsight.com"]},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/eosinophilic-esophagitis-treatment-outlook#faq-question-1673242859637","position":1,"url":"https:\/\/www.delveinsight.com\/blog\/eosinophilic-esophagitis-treatment-outlook#faq-question-1673242859637","name":"1. What is eosinophilic esophagitis?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Eosinophilic Esophagitis (EoE) is a chronic inflammatory ailment that is immune-mediated. It is characterized by an increased number of eosinophils infiltrating the esophagus, thus, impacting one\u2019s fundamental eating ability.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/eosinophilic-esophagitis-treatment-outlook#faq-question-1673242872902","position":2,"url":"https:\/\/www.delveinsight.com\/blog\/eosinophilic-esophagitis-treatment-outlook#faq-question-1673242872902","name":"2. What are the eosinophilic esophagitis symptoms?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Dysphagia, food impaction, and choking\/gagging with meals, particularly when eating coarse textures, are the most common eosinophilic esophagitis symptoms in school-aged children and adolescents, whereas dysphagia is more common in adults. Other eosinophilic esophagitis symptoms include abdominal\/chest pain, vomiting, and regurgitation.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/eosinophilic-esophagitis-treatment-outlook#faq-question-1673242886155","position":3,"url":"https:\/\/www.delveinsight.com\/blog\/eosinophilic-esophagitis-treatment-outlook#faq-question-1673242886155","name":"3. How is eosinophilic esophagitis diagnosed?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"The clinical manifestations of EoE, as well as endoscopic and histological findings in esophageal mucosa biopsies, are used to make the eosinophilic esophagitis diagnosis. Biopsy findings demonstrating increased intra-epithelial esophageal eosinophil counts without concomitant eosinophilic infiltration in the stomach or duodenum remain the gold standard for eosinophilic esophagitis diagnosis.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/eosinophilic-esophagitis-treatment-outlook#faq-question-1673242904796","position":4,"url":"https:\/\/www.delveinsight.com\/blog\/eosinophilic-esophagitis-treatment-outlook#faq-question-1673242904796","name":"4. What are the current eosinophilic esophagitis treatment options?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Eosinophilic esophagitis treatment currently consists of dietary, pharmacological, and endoscopic interventions. PPIs and corticosteroids are the mainstays of treatment in pharmacologic therapy. PPIs and corticosteroids, unfortunately, are associated with a high rate of remission.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/eosinophilic-esophagitis-treatment-outlook#faq-question-1673242929632","position":5,"url":"https:\/\/www.delveinsight.com\/blog\/eosinophilic-esophagitis-treatment-outlook#faq-question-1673242929632","name":"5. Which pharma companies are currently working in the eosinophilic esophagitis treatment domain?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Leading companies, including Bristol Myers Squibb (BMS), Ellodi Pharmaceuticals, AstraZeneca, Kyowa Hakko Kirin, Dr. Falk Pharma GmbH, Regeneron Pharmaceuticals, Sanofi, Allakos, Pfizer, Revolo Biotherapeutics, EsoCap AG, and others are currently evaluating their lead assets in various clinical stages.","inLanguage":"en-US"},"inLanguage":"en-US"}]}},"author_meta":{"display_name":"Sandeep Joshi","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/sjoshidelveinsight-com"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/01\/09111958\/eosinophilic-esophagitis-treatment-outlook-300x187.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">EoE<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Eosinophilic Esophagitis<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">eosinophilic esophagitis market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">eosinophilic esophagitis pipeline<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">eosinophilic esophagitis treatment<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">eosinophilic esophagitis treatment market<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">EoE<\/span>","<span class=\"advgb-post-tax-term\">Eosinophilic Esophagitis<\/span>","<span class=\"advgb-post-tax-term\">eosinophilic esophagitis market<\/span>","<span class=\"advgb-post-tax-term\">eosinophilic esophagitis pipeline<\/span>","<span class=\"advgb-post-tax-term\">eosinophilic esophagitis treatment<\/span>","<span class=\"advgb-post-tax-term\">eosinophilic esophagitis treatment market<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 3 years ago","modified":"Updated 3 years ago"},"absolute_dates":{"created":"Posted on Jan 9, 2023","modified":"Updated on Sep 5, 2023"},"absolute_dates_time":{"created":"Posted on Jan 9, 2023 5:37 pm","modified":"Updated on Sep 5, 2023 5:18 pm"},"featured_img_caption":"eosinophilic-esophagitis-treatment-outlook","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/20675","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=20675"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/20675\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/20676"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=20675"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=20675"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=20675"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=20675"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=20675"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}